Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.
about
Cancer pharmacogenomics: strategies and challengesVascular Complications of Cancer ChemotherapyHypertension in patients with cancerInfluence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer PatientsAssociation Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug ReactionSorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.Anti-VEGF Cancer Therapy in Nephrology PracticeAssociation of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review)eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients.Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients.IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patientsThe contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib.Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis.Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study.Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.
P2860
Q24289309-C5FEC228-4BDA-4E8D-B42C-B3AF0F40474BQ26766269-AC5A79CA-D90C-4E3A-82AA-3C00154B5125Q27003980-E9E0A71C-1D8C-41BA-8EA6-CA69DCC9E5AEQ28080163-0B7BA8AA-8681-4260-9653-5FD160866EE3Q28550377-558860DE-DC39-4B70-9053-DDD0681E819CQ30587082-A641B013-A444-4502-939E-F6DADA87747AQ30986269-A307D5F9-1243-4776-BA21-5A60E67A66C7Q34152125-6101CE50-D4DC-40DC-9018-6D1B53DCB8F7Q35921573-3FCE13FD-CF08-4949-B723-022B689F4E23Q36106439-060E90EA-667F-48D3-A88D-E379BEA60334Q36275134-9B0BD7C0-B186-4C28-ADC8-08B5565A554EQ37265655-392E1FBB-C6F5-4A0E-AE3A-1461FDE98258Q37317462-06F9E4F3-7663-49F9-B191-E39633A53D5AQ37650644-FE688AF0-1E76-4208-B6CE-25F737F28CEFQ37702070-6C158B0A-E8CE-444F-977D-EC48EBE6419EQ37725536-CCB419B3-E4C6-4DE0-AF8C-7FBE36BCC60BQ38925714-6D2DF556-555A-404F-BE2A-75C248C5B61FQ40177329-11E4E159-D149-4A2B-827C-346555837E8EQ41773428-038A6B04-181C-4F9C-9D6F-6868B5A557AEQ41921665-27F67309-F443-4A91-B0B9-FE75D26EC306Q49635743-09E945E2-91C5-4423-ACA9-F9EF695F00CEQ50204127-A29FA2B4-B793-4AEC-A3B2-CB02F7ACC30E
P2860
Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Polymorphisms in endothelial n ...... unitinib-induced hypertension.
@ast
Polymorphisms in endothelial n ...... unitinib-induced hypertension.
@en
Polymorphisms in endothelial nitric oxide synthase
@nl
type
label
Polymorphisms in endothelial n ...... unitinib-induced hypertension.
@ast
Polymorphisms in endothelial n ...... unitinib-induced hypertension.
@en
Polymorphisms in endothelial nitric oxide synthase
@nl
prefLabel
Polymorphisms in endothelial n ...... unitinib-induced hypertension.
@ast
Polymorphisms in endothelial n ...... unitinib-induced hypertension.
@en
Polymorphisms in endothelial nitric oxide synthase
@nl
P2093
P2860
P356
P1476
Polymorphisms in endothelial n ...... unitinib-induced hypertension.
@en
P2093
A A M van der Veldt
A K L Reyners
C M L van Herpen
H Gelderblom
H-J Guchelaar
J A M Wessels
J B Haanen
K Eechoute
M H W Kappers
P2860
P2888
P304
P356
10.1038/CLPT.2012.136
P407
P577
2012-09-05T00:00:00Z
P6179
1013254740